Jefferies Financial Group Inc. lifted its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 35.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,000 shares of the company’s stock after buying an additional 6,475 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Zoetis were worth $1,746,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. First Command Advisory Services Inc. increased its stake in shares of Zoetis by 3,881.8% during the 3rd quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock worth $31,000 after purchasing an additional 427 shares during the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of Zoetis by 1.8% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 12,148 shares of the company’s stock valued at $848,000 after purchasing an additional 218 shares in the last quarter. Inspire Trust Co. N.A. acquired a new stake in shares of Zoetis in the 3rd quarter valued at $3,841,000. Bahl & Gaynor LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at $352,000. Finally, Philadelphia Trust Co. boosted its holdings in Zoetis by 60.5% in the third quarter. Philadelphia Trust Co. now owns 6,426 shares of the company’s stock worth $449,000 after purchasing an additional 2,423 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Wall Street Analyst Weigh In
ZTS has been the subject of a number of analyst reports. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research report on Tuesday, August 25th. Jefferies Financial Group increased their price objective on Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. BTIG Research dropped coverage on Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 price objective on the stock. TD Cowen reduced their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Finally, Piper Sandler decreased their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $101.25.
Get Our Latest Stock Report on Zoetis
Zoetis Stock Performance
Shares of ZTS opened at $83.65 on Monday. The company has a market capitalization of $33.99 billion, a PE ratio of 14.23, a price-to-earnings-growth ratio of 1.21 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49. The company’s fifty day moving average price is $76.28 and its 200 day moving average price is $91.56.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.70 earnings per share. As a group, analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current year.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is currently 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
